Clinical Trial Update: A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) [Phase 2]

View source ↗

Summary

Phase II trial evaluating selinexor with cytarabine and idarubicin in relapsed/refractory acute myeloid leukemia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)
• Selinexor (selinexor)

Snippet

Sponsor: GSO Global Clinical Research BV | Conditions: Acute Myeloid Leukemia (Relapsed/Refractory) | Phase 2 | Status: COMPLETED | Results posted: 2021-08-25